Table 3.

Univariate Odds Ratios (ORs) for Left Ventricular Hypertrophy (LVH) and Diastolic Dysfunction (DD)

Variable	LVH (n = 448)			DD (n = 224)
	OR	95% CI	P value	OR	95% CI	P value
Age, per 10-y increase	1.10	0.92—1.31	.30	1.37	1.06—1.76	.01
Black race	1.22	0.79—1.88	.38	0.76	0.43—1.36	.35
Hypertension	1.56	1.05—2.31	.03	1.21	0.71—2.05	.48
Hyperlipidemia	1.22	0.75—2.00	.42	1.43	0.77—2.66	.25
Diabetes mellitus	1.33	0.83—2.16	.23	1.79	0.94—3.44	.08
Cocaine use	1.45	0.97—2.17	.07	0.88	0.50—1.54	.65
Tobacco use, current	1.25	0.75—2.10	.37	0.49	0.29—0.84	.01
Tobacco use, any	1.19	0.81—1.76	.39	1.40	0.66—2.96	.38
Hepatitis C infection	0.92	0.56—1.52	.75	0.93	0.48—1.79	.82
Time from HIV diagnosis to first TTE, per 5-y increase	0.99	0.85—1.16	.90	1.07	0.87—1.31	.53
ACE inhibitor use	1.44	0.91—2.27	.12	1.30	0.72—2.37	.38
Beta-blocker use	1.76	1.10—2.82	.02	2.01	1.09—3.71	.03
Abacavir exposure	0.73	0.44—1.21	.22	0.86	0.46—1.62	.64
Didanosine/stavudine exposure	1.05	0.68—1.63	.82	1.30	0.69—2.44	.42
Zidovudine exposure	1.10	0.73 — 1.67	.89	0.64	0.36—1.15	.33
PI exposure	0.87	0.59—1.28	.48	0.85	0.50—1.44	.54

ACE, angiotensin-converting enzyme inhibitor; CI, confidence interval; PI, protease inhibitor.